ABSTRACT: The ability of monovalent IgG and F(ab')2 antivenoms to neutralize lethality, phospholipase A2, and coagulant activities induced by Daboia siamensis venom was studied. Both antivenoms were produced from the same batch of hyperimmune horse plasma and were adjusted to the same potency against the lethal effect of D. siamensis venom in experiments involving preincubation of venom and antivenom. Intact neutralization experiments involving independent injection of venom and antivenoms showed that the F(ab')2 antivenom was slightly more effective. Significant differences in favour of F(ab')2 antivenom were observed with respect to neutralization of phospholipase A2 and coagulant activities. Both IgG and F(ab')2 antivenoms were able to activate human complement in vitro. IgG antivenom had a significantly higher anticomplementary activity than F(ab')2 antivenom.
INTRODUCTION
Antivenoms are used regularly worldwide for the treatment of severe snake-bite envenomations 1, 2 . Over the past decade, the availability and quality of snake antivenoms has become an important issue of concern, especially in the rural tropics where the burden of disease is greatest 3 . There seems to be a strong belief that if antivenoms manufactured with good standard will be effective for most snake bites. The methods currently used to prepare these antivenoms have not advanced much from the method originally developed by Pope [4] [5] [6] . Either a monovalent or polyvalent antivenom can be produced from the hyperimmunization of a variety of animals, and is used in the form of whole immunoglobulins or digested with pepsin to produce the F(ab') 2 fraction. However, most manufacturers produce F(ab') 2 antivenoms in order to reduce anaphylactic reactions 7 . Many studies have been conducted to compare the effectiveness of IgG and F(ab') 2 antivenoms to neutralize systemic and local venom effects. Because of a small molecular weight, by pharmacokinetic studies F(ab') 2 fragments have shown a larger volume of distribution and a faster tissue compartment absorption rate than whole IgG antivenoms 8 . These results support the notion that F(ab') 2 antivenoms are more effective than IgG antivenoms at neutralizing venom in tissue. However, some studies show that IgG and F(ab') 2 antivenoms do not differ in their abilities to neutralize the systemic and local effects of Bothrops asper venom [9] [10] [11] [12] [13] [14] . It has been shown by in vitro methods that F(ab') 2 antivenoms have higher anticomplementary activity than IgG precipitated by caprylic acid and thus decreasing the risk of early adverse reactions occurring after antivenom treatment 14, 15 . Regarding side effects and safety of treatment it is important to study a variety of characteristics of the IgG and F(ab') 2 antivenoms.
IgG and F(ab') 2 antivenoms in the previous studies were polyvalent antivenoms. Most studies emphasized the neutralization of lethality and local effects; haemorrhagic, oedema-forming, and myotoxic activities of venom. In contrast to previous studies, here we consider the neutralization of lethality, coagulant, and phospholipase A 2 (PLA 2 ) activities of D. siamensis venom by equine monovalent IgG and F(ab') 2 D. siamensis antivenoms. The PLA 2 , Daboiatoxin is the key lethal component of D. siamensis venom. PLA 2 is a multifunctional enzyme that catalyses the hydrolysis of the fatty acid ester bond at the position 2 of 1,2-diacyl-sn-3-phosphoglycerides to produce free www.scienceasia.org fatty acids and lysophospholipids 16, 17 . Therefore PLA 2 can cause local cell-and tissue-damage, as well as systemic effects in snake bite victims. Antivenom neutralization of PLA 2 , an important component of the venom in the pathophysiology of snake envenoming 16, 18, 19 , deserves attention. Additionally, the anticomplementary activities of equine monovalent IgG and F(ab') 2 antivenoms were studied.
MATERIALS AND METHODS

Venom, antivenom, and animals
Lyophilized Daboia siamensis venom and IgG and F(ab') 2 equine monovalent antivenoms were provided by the Snake Farm and the Production Department of Queen Saovabha Memorial Institute (QSMI). The raw horse hyperimmune plasma against D. siamensis venom was divided into two parts. Part one was whole IgG antivenoms produced by fractionating plasma with caprylic acid precipitation. The another part was F(ab') 2 antivenoms produced by pepsin digestion and followed with caprylic acid precipitation 20 . The venom solution and reconstituted antivenoms were stored at 4°C throughout the duration of the study. Neutralization of phospholipase A 2 activity: The phospholipase A 2 activity of D. siamensis venom was determined by modified indirect haemolytic activity 23, 24 . Briefly, 0.3 ml of packed human erythrocytes washed four times with saline solution, 0.3 ml egg yolk diluted 1:4 in PBS, and 0.25 ml of 0.01 M CaCl 2 were added to 25 ml of 0.8% agarose dissolved in PBS, pH 8.1. The mixture was cooled to 50°C, and then poured into a plastic plate (135 × 80 mm) and allowed to congeal at room temperature. The 3.0 mm diameter wells were filled with 10 µl of venom solution in PBS. Five various dilutions of venom were tested. The plates were incubated at 37°C for 20 h. The corresponding concentration of venom resulting in a 20 mm diameter haemolytic halo was 100% haemolytic activity used for neutralization test. This venom concentration was incubated at 37°C for 30 min with four various dilutions of antivenoms and 10 µl aliquote of each mixture was placed on each well. Each mixture was assayed in triplicate. The plates were incubated at 37°C for 20 h. The average diameter of haemolytic halo was used to calculate the percentage of inhibition of haemolytic activity. The neutralization activity of antivenom was expressed as effective dose 50%, defined as the amount of antivenom (µl) that inhibited 50% of haemolytic activity. 10 µl of PBS solution and 10 µl of antivenom were tested as controls.
Neutralization of coagulant activity: Fifty microlitres of 2LD 50i.v. s venom was incubated at 37°C for 30 min with various amount of antivenom and 0.01 M Tris buffer, pH 7.3 (containing 0.15 M NaCl). The total reaction volume of 100 µl and 100 µl of 0.05 M CaCl 2 were added to 100 µl of plasma. All tubes were placed in the 37°C water bath and the clotting times recorded 25 . As control, the venom (2LD 50i.v. s) incubated with Tris buffer, without antivenom, was done in the same condition. The normal clotting time was recorded when plasma alone was incubated with Tris buffer and CaCl 2 . Neutralization was expressed as the amount (µl) of antivenom at which clotting time was increased to normal clotting time. The clotting times at each amount of either IgG or F(ab') 2 antivenom were also compared. 
Anticomplementary activity
After three times washing with phosphate buffer saline, sheep erythrocytes were resuspended in the same buffer and sensitized by rabbit anti-sheep erythrocyte serum (haemolysin). Seven dilutions of 1 ml antivenoms (either IgG or F(ab') 2 ) in PBS were incubated for 1 h at 37°C with 0.25 ml fresh human serum diluted 1:5 with PBS. Then 0.25 ml of the sensitized erythrocyte suspension was added to each tube and the tubes were incubated for 1.5 h at 37°C. The amount of 1.0 ml of cold PBS was added to each mixture in order to stop the reaction, and then each tube was centrifuged at 700g for 10 min. The corresponding absorbances at 540 nm were recorded 26 . The results were expressed as percentage of remaining complement activity. Controls included incubation of human serum with PBS, in the absence of antivenom (100% complement activity), and incubation of antivenom dilutions with sensitized erythrocytes.
Statistical analysis
Results were expressed as mean ± SD. The mean values of two experimental groups was determined the significance of the differences by the Paired t-test.
RESULTS
Characteristics of antivenoms: IgG and F(ab') 2
After fractionation process, both antivenoms had a minimum potency of 0.6 mg venom/ml antivenom when reconstituted to 10 ml in saline solution. They passed the quality requirements. A band of 100 kDa was observed in a preparation of F(ab') 2 fragments antivenom. While a preparation of IgG antivenom presenting one band of 150 kDa was obtained (results not shown).
Lethality neutralization: Determination of ED 50
In preincubation type experiments, both the IgG and F(ab') 2 antivenoms were able to neutralize the lethality of 2 LD 50iv s D. siamensis venom when injected into the caudal vein of mice over a 24 h period. ED 50 were determined to be 12.4 mg venom neutralized per ml antivenom (95% confidence interval = 11.8-12.9 mg venom/ml antivenom) and 12.4 mg venom/ml antivenom (95% confidence interval = 12.0-12.7 mg venom/ml antivenom) for 10 ml reconstituted IgG and F(ab') 2 antivenoms, respectively.
The results from another series of experiments which antivenoms were administered after envenomation are shown in Table 1 . After intraperitoneal injection of three LD 50ip s of venom, all the mice died at 65.2 ± 3.5 min. When 3 ED 50 s of F(ab') 2 antivenom were administered by the i.v. route immediately, 10, or 30 min after envenomation, neutralization was partial. It showed different pattern for IgG antivenom. All the mice died although three ED 50 s of IgG were immediately administered (Table 1) .
Phospholipase A2 neutralization activity
The concentration of venom that produced a 20 mm diameter haemolytic halo in the erythrocyte egg yolk agarose gel plate was determined to be 4.88 mg venom/ml PBS, pH 8.1. When either IgG or F(ab') 2 antivenom was incubated with this venom concentration, the neutralization of phospholipase activity were observed. The amount of antivenoms that inhibited 50% of haemolytic activity was 183 and 106 µl for IgG and F(ab') 2 antivenoms, respectively. (Fig. 1) .
Coagulant neutralization activity
Human plasma from the donor at the National Blood Bank, Thai Red Cross Society with added Tris buffer had a clotting time of 7.6 ± 0.2 min, whereas human plasma with 7.42 µg of D. siamensis venom had a clotting time of 30 s. Both antivenoms were gradually effective in neutralizing coagulation activity of D. siamensis venom when 1, 2, 4, and 6 µl were added ( Table 2 ). The amount of antivenoms, indicated by plotting the amount of antivenom-clotting time curve www.scienceasia.org a Values correspond to mean ± standard deviation; n = 6. * Significant difference when comparing that amount of IgG and F(ab')2 (p < 0.05).
(not shown), that were used for returning clotting time of human plasma in the presence of venom to normal clotting time were 5.4 and 5.8 µl for IgG and F(ab') 2 , respectively. F(ab') 2 antivenom showed significantly higher neutralizing ability than IgG at the amount of 1, 2, and 4 µl of antivenom (p < 0.05).
Anticomplementary activity of antivenoms
IgG and F(ab') 2 antivenoms showed anticomplementary activity, measured by the consumption of human complement when various dilutions of the antivenoms were incubated with fresh human serum (Fig. 2) . IgG antivenom showed a higher anticomplementary activity than F(ab') 2 antivenom (Fig. 2) . 
DISCUSSION
Nowadays, most antivenoms are either partially purified immunoglobulin (IgG) or F(ab') 2 depending on the method of refinement (extraction with caprylic acid or traditional digestion with pepsin). This has raised the question which is preferred between IgG or F(ab') 2 antivenoms. Some studies using Bothrops asper venom show that IgG and F(ab') 2 antivenoms do not differ in their abilities to neutralize venom with respect to systemic and local effects 9, 10 . However, as an antivenom producer, it is important to produce the most effective antivenoms with minimal side effects. Our present studies were performed to compare the differences in D. siamensis IgG and F(ab') 2 antivenoms produced by QSMI.
The preincubation type assays carried out in mice have shown that IgG and F(ab') 2 antivenoms do not differ in their ability to neutralize 2LD 50iv s of D. siamensis venom. Similar results were observed by Morais et al 9 and León et al 10, 14 when the ability of IgG and F(ab') 2 antivenoms to neutralize the lethal activity of Bothrops species venoms were compared. The pharmacokinetic evidence showed that F(ab') 2 has a large volume of distribution and reach the tissue compartment faster 8, [27] [28] [29] . The finding suggested that F(ab') 2 antivenom might be more effective than IgG antivenom in neutralizing lethal toxicity of venoms.
This pharmacokinetic characteristics may explain the results of our experiments with less lethality using F(ab') 2 antivenom indicating better neutralization shown in Table 1 . It was observed that lethality induced by D. siamensis venom were partially neutralized if F(ab') 2 antivenom was administered immediately or 10 min after envenomation. Under the experimental conditions, the different results are considered to be due to pharmacokinetic parameters and not to variations in ED 50 .
To confirm the differences in neutralizing ability of both antivenoms, neutralization of PLA 2 , coagulation activities ( Fig. 1 and Table 2 ) in D. siamensis venom, anticomplement activity (Fig. 2 ) of IgG and F(ab') 2 antivenoms were tested. Effective dose of F(ab') 2 in neutralizing PLA 2 activity was significantly lower than IgG. This is consistent with neutralization of lethality tested by independent injection of venom and antivenom which could reflect the better binding of small F(ab') 2 molecule to the binding site of PLA 2 molecule than the larger IgG molecule. The same explanation goes to the better neutralization of coagulant activity of F(ab') 2 over IgG antivenoms.
Antivenoms are composed of antibodies from immunized horses. The use of heterologous proteins, horse antibodies, for treatment results in the possibility of adverse reactions. Dependent on the dose, route and speed of administration, and the quality of refinement, the reactions may vary from mild symptoms like chills, nausea, and fever, to serious problems such as bronchospasms and anaphylactic shock. Adverse reactions after antivenom administration are of clinical concern 25, 30 . The occurrence of adverse reactions has been reported to range from 6% up to 87% in different type of antivenoms [31] [32] [33] . Although the cause of these reactions are unclear, complement activation by antivenom proteins has been proposed to be the cause. Complement activation has been described in patients receiving either heterologous or homologous immunoglobulins. In vitro detection of complement activation by antivenoms has been used to predict their anticomplementary activity associated with potential adverse reactions in vivo 34 . The present investigations show that both antivenoms activate human complement in vitro, although F(ab') 2 had lower anticomplementary activity. This would indicate that removal of the Fc fragment of equine immunoglobulins by pepsin digestion reduced, but did not eliminate, anticomplementary activity. This has been previously observed 9, 14, 34 . Besides anticomplementary activity, immune response against heterologous protein were performed in the previous study of León et al 14 . A single intravenous dose of either IgG or F(ab') 2 equine antivenoms was injected into mice. Then, the antibody response to equine immunoglobulin was tracked using ELISA technique weekly during one month. Higher anti-immunoglobulin titres against IgG were presented in mice injected with IgG than in those receiving F(ab') 2 antivenom when plates were coated with equine IgG. No significant differences in antibody titres were detected between the groups when plates were coated with F(ab') 2 antivenom. This would suggest that the presence of an intact Fc does not enhance an anti-immunoglobulin response to F(ab') 2 fragments. The results of anticomplementary activity and immune response to antivenoms indicate that the presence of Fc in immunoglobulins are not the predominant factor in the development of adverse reactions after receiving antivenoms. None of the animals receiving whole IgG antivenom in the study of Estrada et al 35 showed any evidence of early adverse reaction. The factors might include the physicochemical condition of the immunoglobulins, the presence of molecular aggregates, and the total load of protein administered.
In this investigation, our prepared IgG and F(ab') 2 antivenoms were equally effective antivenoms. They were adjusted to have the same potency and the preincubation assay was performed in test tube. The antibodies in antivenoms reacted directly with venoms without influences from the body system. The same potency of both antivenoms neutralized the same amount of venoms. In the other experiment, the situation model of snake bite was performed in mice by the independent injection of venom and antivenom type assay. The single dose of antivenom was selected for the neutralization of lethality in order to express the difference in neutralizing ability between IgG and F(ab') 2 antivenoms. However, the neutralization of lethality in human envenomations, the repeated doses of antivenom is needed.
The following conclusions were drawn from the study: (1) No significant difference was observed between whole IgG and F(ab') 2 antivenoms in their ability to neutralize lethal toxicity of D. siamensis venom by in vitro test. (2) F(ab') 2 antivenom was more effective in inhibiting PLA 2 and coagulation activity. (3) Intact neutralization ability (in vivo neutralization) against lethality of venom by F(ab') 2 antivenom is more effective than IgG antivenom. (4) F(ab') 2 antivenom showed a lower anticomplementary activity than IgG antivenom. The results of the present study suggest that the appropriated form of snake antivenoms should be F(ab') 2 fragments. Saovabha Memorial Institute, Thai Red Cross Society (Project SN5301). The authors would like to thank our colleagues at Queen Saovabha Memorial Institute for their collaboration.
